First Anti-Addiction App Approved In The US
Pear Therapeutics' reSET mobile application to treat substance addictions in combination with outpatient therapy programs has been approved by US FDA. The agency approved the software after a multi-site clinical trial showed patients were significantly more successful remaining abstinent after using the app.
You may also be interested in...
US FDA official questions whether problem is due to population selection, outcome measures, or study duration. Potential endpoints include change in disease status as measured by DSM-5 criteria, cognitive function and quality of life, experts say.
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.
The new alliance is focused on developing a "digital therapeutic" for the treatment of depression. They hope it will take its place as an effective option among current drug and other cognitive therapies.